Bharat Biotech
| Primary URL | Location | Industry | www[.]bharatbiotech[.]com |
Country
India
|
Pharmaceuticals
|
|---|
Profile
Bharat Biotech is an Indian biotechnology company that focuses on the research, development, and manufacture of vaccines for infectious diseases. Its product portfolio includes vaccines for COVID‑19, rotavirus, hepatitis B, typhoid, and poliomyelitis, among others, which are produced using platforms such as Vero cell culture and adjuvant‑based formulations. The company supplies its vaccines to India’s national immunisation programme and also exports to governments and procurement agencies in multiple regions across Asia, Africa, and Latin America. Its headquarters are located in Hyderabad, Telangana, India.
The firm was founded in 1996 by Dr. Krishna Ella and Suchitra Ella and operates as a privately held enterprise without a publicly listed parent or subsidiary structure. Bharat Biotech maintains manufacturing facilities in Gujarat, Telangana, and Karnataka, enabling it to produce large volumes of doses for both domestic and international markets. While specific employee counts or annual revenue figures are not provided in the source material, the company is recognised as a key supplier of vaccines to the Indian government and has participated in global vaccine initiatives such as COVAX. Its role in the COVID‑19 pandemic included the co‑development of Covaxin (BBV152) with the Indian Council of Medical Research‑National Institute of Virology.
Bharat Biotech is distinguished by its expertise in adjuvant technology and its ability to rapidly scale vaccine production during public health emergencies. The company’s capabilities were highlighted during a February 2021 cyberespionage incident, when a Chinese state‑backed hacking group targeted its IT systems alongside another Indian vaccine manufacturer, underscoring its strategic importance to the nation’s pandemic response. This event, reported by a security firm, did not detail any operational disruption or data breach but affirmed the organisation’s prominence in the vaccine sector. The firm continues to concentrate on advancing vaccine candidates for emerging infectious diseases while maintaining its focus on quality, affordability, and accessibility.